Genmab — Januar 2019
-
Måske begge to: BMS pounces on Prostvac with $975m option deal
BMS has paid $60m for an option to license exclusive rights to Prostvac and could pay a further $915m in milestones. Importantly, in our view the deal significantly expands Prostvac’s potential, with BMS’ marketing strength, immuno-oncology expertise and the potential to combine Prostvac with a pipeline of opportunities -
Hej og godt nytår til alle. Hvis en Celgene aktie pt. kan købes til under 81$ og byttes ved handlen til en BMS aktie til over 44 samt 50$ i cash har vi en difference over 13$ Hvordan giver det mening? Skulle man købe op i Celgene for at lave en hurtig gevinst, eller ligger der stadig en usikkerhed af en slags?
?!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind